Case report: Analysis of novel compound heterozygous TPP1 variants in a Chinese patient with neuronal ceroid lipofuscinosis type 2

Sui-Bing Miao¹, Hui Guo², De-Xian Kong³, Yuan-Yuan Zhao¹, Shu-Hong Pan¹, Yan Jiang⁴, Xing Gao⁴ and Xiao-Hua Wu¹*

¹Key Laboratory of Maternal and Fetal Medicine of Hebei Province, Institute of Reproductive Medicine of Shijiazhuang, The Fourth Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China, ²Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Hebei Medical University Shijiazhuang, Shijiazhuang, China, ³Department of Endocrinology, The Fourth Affiliated Hospital of Hebei Medical University Shijiazhuang, Shijiazhuang, China, ⁴Center of Reproductive Medicine, The Fourth Hospital of Shijiazhuang Affiliated to Hebei Medical University, Shijiazhuang, China

Neuronal ceroid lipofuscinosis type 2 (CLN2) is an autosomal recessive neurodegenerative disease caused by variants in the TPP1 gene that lead to the deficiency of the lysosomal enzyme tripeptidyl peptidase I (TPP1) activity. Herein, we report a rare case of CLN2 caused by two novel variants of TPP1. The patient presented with seizures at onset, followed by progressive cognitive impairment, motor decline, and vision loss. Novel compound heterozygous variants, c.544_545del and c.230-3C>G, in TPP1 were identified by whole-exome sequencing. The variant assessment showed that the c.544_545del is a frameshift variant mediating mRNA decay and that c.230-3C>G is a splice variant generating aberrantly spliced TPP1 mRNA, as confirmed by a Splicing Reporter Minigene assay. In conclusion, clinical history, variant assessment, and molecular analyses demonstrate that the novel compound heterozygous variants are responsible for CLN2 disease in this patient. This study expands the mutation spectrum of TPP1.

KEYWORDS
neuronal ceroid lipofuscinosis type 2 (CLN2), tripeptidyl peptidase I (TPP1), variant, molecular analysis, splicing assay

Introduction

Neuronal ceroid lipofuscinoses (NCL; CLN) are a clinically and genetically heterogeneous group of autosomal recessive progressive neurodegenerative disorders characterized by the accumulation of autofluorescent lipopigment storage material in lysosomes. They have an estimated worldwide incidence of 1–4/100,000 (Simonati et al., 2017). The main clinical features of this disease include epileptic seizures, cognitive decline, motor deterioration, progressive visual
failure, and shortened life expectancy (Johnson et al., 2019). NCLs are classified into four major types: infantile, late-infantile, juvenile, and adult-onset, by age at onset. Thirteen causal genes have been identified so far (Gardner and Mole, 2021).

Neuronal ceroid lipofuscinosis type 2 (CLN2), also known as classical late-infantile neuronal ceroid lipofuscinosis (LINCL), is caused by mutations in TPP1, which encodes lysosomal tripeptidyl peptidase I (TPP1) (Yu et al., 2015). TPP1 is mapped to chromosome 11p15. It consists of 13 exons and has a length of 13,696 bp (NG_008653.1). To date, 155 unique variants in TPP1 have been identified (www.ucl.ac.uk/ncl-disease/mutation-and-patient-database). TPP1 is a lysosomal enzyme of 563 amino acids that specifically removes three amino acids from the N termini of proteins undergoing degradation in lysosomes (Vines and Warburton, 1999; Lin et al., 2001). Deficiency of TPP1 results in the accumulation of autofluorescent lipopigments in lysosomes, which is the typical pathomorphological change of all NCLs (McLaren et al., 2019).

Herein, we report a case of CLN2 with two novel TPP1 variants, one frameshift and one splice variant, from a Chinese family. The variants were classified as pathogenic and likely pathogenic by analyzing their functional consequences and according to the American College of Medical Genetics and Genomics (ACMG) guidelines. Our study expands the mutation spectrum for TPP1 and provides the functional consequences of the novel splice variant.

Methods

Whole-exome sequencing

Genomic DNA was extracted from peripheral blood by the Blood DNA Kit V2 (CW25538, Cowin Bio, China). DNA samples were quantified with a Qubit dsDNA HS Assay Kit (Q32851, Invitrogen, United States). The quantified DNA samples were fragmented into 200–300 bp fragments and then processed for DNA library preparation with a KAPA Library Preparation Kit (KR0453, Roche, United States) according to the manufacturer’s protocol. Hybridization of the prepared libraries to capture probes was carried out according to the instructions for the xGen Exome Research Panel v2.0 (Integrated DNA Technologies Inc., United States). The captured DNA samples were then cloned into the minigene vector pMini-CopGFP (Hitrobio.tech, China) with a ClonExpress II One Step Cloning Kit (Vazyme, Nanjing, China). The following primers were used to construct the vectors: TPP1-F, AAG CTTGGTACCCGGACGCTCAGGATCCGGTCGAAGAGGCTG GGTGCCTCGG; TPP1-R, TTAAACGGGGCTCTCTAGA CTCGAGCAAAGTCCACATGGGGCCAAGGCC. WT and MT constructs were identified by sequencing. The WT and MT plasmids were transfected into the HEK293T cell line for 48 h. Total RNA was extracted using TRIzol reagent (Ccowin Biotech Co., Ltd., Taizhou, China). cDNA synthesis was performed using a HiScript II 1st Strand cDNA Synthesis Kit (R212-01, Vazyme Biotech, China). PCR amplifications were performed with the primers F-GGCTAACCTAGAACCCTACCTGTTA and R- CA AGTCCACATGGGGCCAAGGCC. The PCR products were separated by electrohoresis and analyzed by Sanger sequencing (Gaidrat et al., 2010).

Bioinformatics analysis

Raw data were processed by Fastp to remove adapters and filter low-quality reads. The qualified reads were aligned to the human reference sequence GRCh37/hg19 by BWA. Single nucleotide variants and insertions and deletions were called by GATK. Population and disease databases were used to obtain the frequencies of variants in large populations. The variants with allele frequency > 1% were filtered out. The ClinVar and HGMD databases were queried to identify previously reported cases with the variants. Multiple in silico algorithms were utilized to predict the pathogenicity of the candidate variants. Candidate variants were classified according to the ACMG guidelines (Richards et al., 2015). The version of ReSeq transcript accession used in the TPP1 variant assessment was NM_000391.4.

Sanger sequencing

Sanger sequencing was performed to validate the variants identified by WES. PCR primers were designed by Primer Premier 5.0 and are available upon request. PCR amplification was conducted with standard methods. The PCR products were purified and sequenced with an ABI 3730 DNA Sequencer (Applied Biosystems, United States), and the sequencing results were analyzed with Chromos Lite v2.01.

Splicing Reporter Minigene assay

Genomic segments encompassing position c.230-3 (NM_000391.4) along with flanking intronic sequences spanning exons 3–5 and introns 3–4 in TPP1 were amplified by PCR from the genomic DNA of the patient’s mother, who was the c.230-3C>G variant carrier. The wild-type (WT) c.230-3C and mutant (MT) c.230-3G sequences were then cloned into the minigene vector pMini-CopGFP (Hitrobio.tech, China) with a ClonExpress II One Step Cloning Kit (Vazyme, Nanjing, China). The following primers were used to construct the vectors: TPP1-F, AAG CTTGGTACCCGGACGCTCAGGATCCGGTCGAAGAGGCTG GGTGCCTCGG; TPP1-R, TTAAACGGGGCTCTCTAGA CTCGAGCAAAGTCCACATGGGGCCAAGGCC. WT and MT constructs were identified by sequencing. The WT and MT plasmids were transfected into the HEK293T cell line for 48 h. Total RNA was extracted using TRIzol reagent (Ccowin Biotech Co., Ltd., Taizhou, China). cDNA synthesis was performed using a HiScript II 1st Strand cDNA Synthesis Kit (R212-01, Vazyme Biotech, China). PCR amplifications were performed with the primers F-GGCTAACCTAGAACCCTACCTGTTA and R- CA AGTCCACATGGGGCCAAGGCC. The PCR products were separated by electrohoresis and analyzed by Sanger sequencing (Gaidrat et al., 2010).
Results

Case presentation

The patient, a male with unremarkable antenatal and perinatal history, was taken to the hospital for the treatment of seizures at the age of 3. Until then, he had developed normally. Subsequently, progressive cognitive disorder, neuromotor dysfunction, and vision problems appeared gradually. Unsteady gait was observed at the age of 3–4 years, followed by increasing difficulties in walking, talking, and swallowing. His conditions continued to deteriorate over time. His sight and ability to stand and vocalize were lost at a later stage, and he ultimately died at the age of 8 (Figure 1A). CT showed mild brain atrophy, and MRI revealed that the T2 signal of the bilateral posterior horn of the lateral ventricle was slightly extended. EEG
demonstrated a slow and irregular rhythm of background and epileptic discharges. The patient had been treated with carbamazepine and received rehabilitation therapy, but the treatments were ineffective. The pedigree of the family is shown in Figure 1B. The proband was born to healthy parents with an unremarkable family history.

**Variant analysis**

To explore the underlying genetic basis, WES was carried out to examine the exome of the patient. Two novel variants, c.544_545del and c.230-3C>G, in *TPP1* were found. The variants were then confirmed in the family by Sanger sequencing. The sequencing results showed that the c.544_545del variant was inherited from the father and that the c.230-3C>G variant was inherited from the mother (Figure 2). Next, the variants were classified according to ACMG guidelines (Richards et al., 2015). The c.544_545del variant was interpreted as pathogenic. The available evidence supporting this interpretation is as follows: it is a frameshift variant and nonsense-mediated mRNA decay (NMD) is predicted to occur (PM2_Supporting). The frequency of this variant is extremely low in the general population (PM2_Supporting).
The phenotype of the patient is specific to the disease related to the gene (PP4). However, the pathogenicity of the other variant, c.230-3C>G, was predicted to be of uncertain significance based on available evidence. The variant was detected in trans with a pathogenic variant (PM3) and predicted to be deleterious by multiple lines of computational evidence (PP3) and PM2_Supporting and PP4.

Given that the proband is presented with typical symptoms of CLN2, which follows an autosomal recessive inheritance pattern (Goebel and Sharp, 1998), we speculated that the variant c.230-3C>G might also be pathogenic. To further clarify the pathological significance of the c.230-3C>G variant, we determined the impact of the variant on transcript splicing using the Splicing Reporter Minigene assay (Hartikainen et al., 1999; Yuan et al., 2021). The RT-PCR products were analyzed by electrophoresis, and the results showed that the length of the PCR product was shortened in the MT construct (Figure 3A), indicating that aberrant splicing occurred. The sequencing result of the excised gel bands confirmed the absence of the sequence of exon 4 of 151 nt in length in the MT construct (Figure 3B). The Minigene assay demonstrated that the c.230-3C>G substitution abrogates the intron 3 canonical acceptor splice site and results in the skipping of exon 4 (c.230_380del) (Figure 3C). This alteration is predicted to lead to an in-frame deletion of amino acids and changes in protein structure (Figure 3D). Thus, we could add PS3 evidence (well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product) for the variant interpretation, and the c.230-3C>G variant could be classified as likely pathogenic accordingly.

Discussion

CLN2 is currently believed to be caused by the loss or reduction of TPP1 activity due to mutations in TPP1 (Wang et al., 2011). This report presents a patient with classical LINCL manifestations, including uncontrolled seizures, cognitive impairment, motor deterioration, and progressive vision loss. Two novel variants, c.544_545del and c.230-3C>G in TPP1, were identified by WES and Sanger sequencing. According to ACMG guidelines, the c.544_545del variant was classified as pathogenic based on available evidence, and c.230-3C>G was interpreted as likely pathogenic by the Splicing Reporter Minigene assay.

The structure of the TPP1 protein contains an activation domain (residues 33–176) and a catalytic domain (residues 257–496), which compose the proenzyme form of TPP1. Upon acidification, the inactive proenzyme form is transformed into a mature enzyme by releasing the catalytic domain from the C-shaped structure formed by the activation domain (Pal et al., 2009; Gardner et al., 2019). Although the pathological mechanisms underlying CLN2 disease remain unclear, the majority are likely linked to loss of enzyme activity (Gardner et al., 2019). The c.544_545del variant is predicted to cause protein truncation (p.L182Efs*5). This truncation leads to the loss of the whole catalytic domain or nonsense-mediated mRNA decay according to NMD mechanisms (Broagna and Wen, 2009; Kurosaki et al., 2019) (http://autopvs1.genetics.bgi.com/variant/hg19/11-6638347-CAG-C:NM_000391.4). The c.230-3C>G variant can result in the skipping of exon 4. Codons of residues 77–127 in the primary structure of the protein TPP1 are in exon 4. Hence, the deletion of exon 4 due to the splice variation can result in damage to the activation domain and abnormalities in activating the enzyme. Collectively, we speculate that the two novel variants could cause a loss of enzyme activity. This could lead to substrate degradation failure within lysosomes and cause lysosomal storage disease.

WES is now becoming the main method for detecting mutations; however, correct interpretation of the numerous detected mutations is still challenging (Suwinski et al., 2019). Compared with the sequencing process, bioinformatics analysis and variant interpretation are more critical in the diagnosis of rare diseases (Nguyen and Charlebois, 2015). Sequencing is just the beginning of a genetic diagnosis, which often requires multiple analysis steps. This process takes a long time, and clinicians usually need to maintain communication with the clinical laboratory during the diagnosis process. In this case, the variants of TPP1 were overlooked at disease onset because the patient only showed the first clinical symptom of seizures when WES was conducted. With the typical symptoms of LINCL appearing, such as cognitive decline and motor deterioration, variant reassessment was performed, and the variants c.544_545del and c.230-3C>G were finally identified. However, because one of the variants was classified as having uncertain significance based on available evidence, we could not conclude the cause of the patient’s symptoms. Next, a functional study was conducted, confirming that the intron variant c.230-3C>G could cause exon loss due to splicing variation. Only then was the pathogenicity of both variants confirmed, and the diagnosis was made by a comprehensive analysis of the clinical features, history, and interpretation of the variants.

In summary, c.544_545del and c.230-3C>G were confirmed as the causative variants for CLN2. Our study expands the spectrum of TPP1 variants and provides a classification of the pathogenicity of the variants. In addition, this report attempts to highlight the continuity and complexity of the diagnostic process of genetic diseases through this report.

Data Availability Statement

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.
**Ethics Statement**

The studies involving human participants were reviewed and approved by the Shijiazhuang Fourth Hospital Ethics Committee. Written informed consent was obtained from the patient’s legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

**Author contributions**

S-BM and X-HW conceived and designed the study, S-BM drafted the manuscript. D-XK, XG, and YJ collected the clinical information of the patient. HG, S-HP, and Y-YZ performed the laboratory work. All authors contributed to the manuscript revision and read and approved it for publication.

**Funding**

This study was funded by the Natural Science Foundation of Hebei Province (no. C2021106015), the Key Research and Development Project of Hebei Province (no. 213777101D), the Medical Science Research Project of Hebei Province (no. 20211207).

**Acknowledgments**

We thank our patient and his family.

**Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**References**

Brogna, S., and Wen, J. (2009). Nonsense-mediated mRNA decay (NMD) mechanisms. *Nat. Struct. Mol. Biol.* 16, 107–113. doi:10.1038/nsmb.1550

Gaillard, P., Källman, A., Martins, A., Tourrier, I., Fr Bourg, T., and Tosi, M. (2010). Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants. *Methods Mol. Biol.* 653, 249–257. doi:10.1007/978-1-60761-759-4_15

Gardner, E., Bailey, M., Schulz, A., Aristorenas, M., Miller, N., and Moel, S. E. (2019). Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. *Hum. Mutat.* 40, 1924–1938. doi:10.1002/humu.23660

Gardner, E., and Moel, S. E. (2021). The genetic basis of phenotypic heterogeneity in the neuronal ceroid lipofuscinoses. *Front. Neurol.* 12, 754045. doi:10.3389/fneur.2021.754045

Goebel, H. H., and Sharp, J. D. (1998). The neuronal ceroid-lipofuscinoses. Recent advances. *Brain Pathol.* 8, 151–162. doi:10.1111/j.1750-3639.1998.tb00142.x

Hartikainen, J. M., Ju, W., Wisniewski, K. E., Moroziewicz, D. N., Kaczmarski, A. L., McLendon, L., et al. (1999). Late infantile neuronal ceroid lipofuscinosis is due to splicing mutations in the CLN2 gene. *Mol. Genet. Metab.* 67, 162–168. doi:10.1006/mgme.1999.2853

Johnson, T. B., Cain, J. T., White, K. A., Ramirez-Montealegre, D., Pearce, D. A., and Weimer, J. M. (2019). Therapeutic landscape for batten disease: Current treatments and future prospects. *Nat. Rev. Neurol.* 15, 161–178. doi:10.1038/s41582-019-0138-8

Kurosaki, T., Popp, M. W., and Maquat, L. E. (2019). Quality and quantity control of gene expression by nonsense-mediated mRNA decay. *Nat. Rev. Mol. Cell Biol.* 20, 406–420. doi:10.1038/s41580-019-0126-2

Lin, L., Sohar, I., Lackland, H., and Lobel, P. (2001). The human CLN2 protein/ tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. *J. Biol. Chem.* 276, 2249–2255. doi:10.1074/jbc.M008562200

Mcclare, M. D., Mathavaranaj, S., and Huber, R. J. (2019). Recent insights into NCL protein function using the model organism *Drosophila discoidenum*. Cells 8, 115. doi:10.3390/cells8020115

Nguyen, M. T., and Charlebois, K. (2015). The clinical utility of whole-exome sequencing in the context of rare diseases - the changing tides of medical practice. *Clin. Genet.* 88, 313–319. doi:10.1111/cge.12546

Pal, A., Kratzner, R., Grune, T., Grapp, M., Schreiber, K., Gr Nborg, M., et al. (2009). Structure of tripeptidyl-peptidase I provides insight into the molecular basis of late infantile neuronal ceroid lipofuscinosis. *J. Biol. Chem.* 284, 3976–3984. doi:10.1074/jbc.M806947200

Richards, S., Aziz, N., Bale, S., Dicks, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. *Genet. Med.* 17, 405–424. doi:10.1038/gim.2015.30

Simonati, A., Williams, R. E., Nardocci, N., Laine, M., Battini, R., Schulz, A., et al. (2017). Phenotype and natural history of variant late infantile ceroid-lipofuscinosis. *S. Dev. Med. Child. Neurol.* 59, 815–821. doi:10.1111/dmcn.13473

Soswinski, P., Ong, C., Ling, M. H. T., Poh, Y. M., Khan, A. M., and Ong, J. S. (2019). Advancing personalized medicine through the application of whole exome sequencing and big data analytics. *Front. Genet.* 10, 49. doi:10.3389/fgene.2019.00049

Vines, D. J., and Warburton, M. J. (1999). Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. *FEBS Lett.* 443, 131–135. doi:10.1016/S0014-5793(99)01683-4

Wang, Y. L., Zeng, Z. Y., Song, X. W., Hao, Z. F., Shi, Y. W., Tang, B., et al. (2011). A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis. *Neurogenetics* 12, 93–95. doi:10.1007/s10048-010-0258-1

Yu, F., Liu, X. M., Chen, Y. H., Zhang, S. Q., and Wang, K. (2015). A novel SCN5A mutation in a patient with late infantile neuronal ceroid lipofuscinosis. *Neurosci. Lett.* 36, 1719–1917. doi:10.1016/j.neulet.2015.2272-4

Yuan, M., Guo, Y., Xia, H., Xu, H., Deng, H., and Yuan, L. (2021). Novel SCN5A and GPD1L variants identified in two unrelated han-Chinese patients with clinically suspected brugada syndrome. *Front. Cardiovasc. Med.* 8, 758903. doi:10.3389/fcvm.2021.758903